Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A new biosynthesis procedure for pharmaceutically active gamma-aminobutyric acids

Objective

Chiral γ-aminobutyric acids (GABAs) represent abundantly prescribed drugs, which are broadly applied as anticonvulsants, antidepressants and for the treatment of neuropathic pain. With the incorporation of more population to western-based style in the coming decades, there is a need of developing and producing pharmaceutically active GABAs and similar (or generic) drugs for higher number of consumers. Supported by an ERC starting grant, Prof. Poelarends has developed an efficient, enzyme-based procedure for the enantioselective synthesis of a wide variety of GABAs. The PoC grant will allow Prof. Poelarends to identify those opportunities in the huge pharmaceutical/generics market where his novel synthesis procedure for pharmaceutically active GABAs provides unique advantages over existing industrial synthesis strategies, in terms of performance, sustainability and economics. To enable the next step towards commercialization, a strong and commercially attractive IP position will be built and a portfolio will be assembled in which the performance of the new technology is compared to current industrial production strategies using extensive market research and demonstration studies. Ultimately, the hope is to license our technology to existing pharmaceutical/generics companies.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2015-PoC

See all projects funded under this call

Host institution

RIJKSUNIVERSITEIT GRONINGEN
Net EU contribution
€ 150 000,00
Address
Broerstraat 5
9712CP Groningen
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 150 000,00

Beneficiaries (1)